Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
MedPage Today on MSN
Targeted Duo Wins Again in BRAF-Mutant Colorectal Cancer
SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, reveals how AI is being used to identify early-onset CRC and enhance ...
Delayed musculoskeletal symptoms after breast radiotherapy can reflect osteoradionecrosis rather than recurrence, thus ...
Revolution Medicines surged on AbbVie buyout rumors but pulled back after denial. Learn what's next for RVMD stock and why it ...
As of Wednesday, January 07, Cardiff Oncology, Inc.’s CRDF share price has surged by 6.36%, which has investors questioning if this is right time to sell.
NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa ...
Hyperfine, Inc. , the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback